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Abstract
Summary Magnesium has a key role in osteoporosis and
could enhance implant osseointegration in osteoporotic pa-
tients. Titanium implants impregnated with Mg ions were
installed in the tibia of ovariectomized rats. The release of
Mg induced a significant increase of bone formation and the
expression of anabolic markers in the peri-implant bone.
Introduction The success of endosseous implants is highly
predictable in patients possessing normal bone status, but it
may be impaired in patients with osteoporosis. Thus, the ap-
plication of strategies that adjuvate implant healing in
compromized sites is of great interest. Magnesium has a key
role in osteoporosis prevention and it is an interesting candi-
date for this purpose. In this study, the cellular and molecular
effects of magnesium release from implants were investigated
at the early healing stages of implant integration.
Methods Osteoporosis was induced in 24 female rats by
means of ovariectomy and low-calcium diet. Titanium mini-
screws were coated with mesoporous titania films and were
loaded with magnesium (test group) or left as native (control
group). The implants were inserted in the tibia and femur of
the rats. One, 2 and 7 days after implantation, the implants
were retrieved and histologically examined. In addition, ex-
pression of genes was evaluated in the peri-implant bone tis-
sue at day 7 by means of quantitative polymerase chain reac-
tions with pathway-oriented arrays.
Results The histological evaluation revealed that new bone
formation started already during the first week of healing for
both groups. However, around the test implants, new bone
was significantly more abundant and spread along a larger
surface of the implants. In addition, the release of magnesium
induced a significantly higher expression of BMP6.
Conclusions These results provide evidence that the release of
magnesium promoted rapid bone formation and the activation
of osteogenic signals in the vicinity of implants placed in
osteoporotic bone.
Keywords Implant surface . In vivo .Magnesium .
Mesoporous titania . Osseointegration . Osteoporosis
Introduction
Osteoporosis is a skeletal disease characterized by decrease in
bone mass and density and abnormalities in bone
microarchitecture, which results in increased susceptibility to
fractures [1]. Osteoporosis is a relevant public health issue,
which affects up to 50% of women and 20% of men in the
white population over the age of 50 [1]. The prevalence in-
creases with age and is gender-related and on the basis of
radiographic evidence almost all observed women by the
age of 75 show a moderate to severe osteoporosis [2].
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Bone mineral density (also referred to as Bbone mass^) is
the result of genetic asset, but it is also strongly influenced by
environmental factors, such as availability of calcium and vi-
tamin D, mechanical loading and age [3]. A decrease in bone
mass is observed when an uncoupling of bone formation and
bone resorption occurs during the physiological process of
skeletal remodelling, with a prevalence of the resorption phase
over the formation phase [1]. The first recognized etiological
factor for this type of bone loss is oestrogen deficiency.
Oestrogens have a regulatory role on bone remodelling, and
they control especially the differentiation and activation of
osteoclasts through several molecular pathways, keeping bone
resorption within physiological range [4]. In women after
menopause, due to the decrease in oestrogen levels, the
oestrogen-mediated regulation is impaired and the osteoclast
activity raises [4]. However, other oestrogen-independent
mechanisms, mostly of which are age-related, can induce
bone loss as well [5].
Osteoporosis may represent a risk for the osseointegration
of endosseous implants [6–8] as bone may be too rarefied to
offer good implant primary stability, one of the pre-requisites
for osseointegration [9].
Although data from available literature suggests that oste-
oporosis is not an absolute contraindication to oral and ortho-
paedic implant placement [10, 11], there is certain evidence
that this disorder may increase the rate of implant failure.
It has been shown that postmenopausal women had statis-
tically significantly higher implant failure in the maxilla com-
pared to premenopausal women and men older than 50
(13.6% of failure vs. 6.3 and 7.6%) [12]. However, if the
osteoporotic women had received oestrogen supplementation,
their implant failure rate was lower than in postmenopausal
women without hormone replacement treatment (13.6 vs.
8.1%) [12]. No difference was observed for implant placed
in the mandible [12].
Furthermore, evidence exists that osteoporosis could repre-
sent a threat to osseointegration when associated with other
risk factors, such as smoking, diabetes mellitus or bruxism,
which together may increase considerably the risk of implant
failure [6].
Therefore, the development of protocols and materials
targeted to improve performances in patients with osteoporo-
sis is still of primary interest.
One strategy to improve the long-term fixation of implants
in osteoporotic sites has been to functionalize the implant
surfaces, to stimulate peri-implant osteogenesis [13].
A promising approach in this scenario has been the inclu-
sion of bone resorption inhibitors of the bisphosphonate class
(raloxifene and alendronate) loaded into mesoporous coatings
deposited onto titanium implants. The coatings provided a
sustained release of the drugs directly at the healing site with
the effect of enhancing the bone anchorage of the implants
in vivo [14, 15].
However, a potential risk of bisphosphonates is to induce
osteonecrosis, a condition documented especially in the jaws
[16]. Although this adverse effect has been so far associated
only with high doses of the drugs in systemic applications, no
clinical evidence exists that indicates local application as a
risk-free solution; therefore, an alternative doping material
would be of great interest [17].
One of the possible candidates for doping implant surfaces
is magnesium (Mg), which has been reported to significantly
increase the bone-implant fixation in vivo and in clinical situ-
ations [18–20]. In previous studies, we have documented the
osteoconductive and osteogenic potential of magnesiumwhen
released from mesoporous titania surfaces and confirmed the
associated increase of bone formation and biomechanical an-
chorage [21–23].
Of particular interest is whether magnesium availability has
a key role in osteoporosis. Magnesium is strongly involved in
bone metabolism, both as a mitogen factor for osteoblasts,
which proliferate in the presence of magnesium, and as pro-
tective factor from excessive bone resorption [24].
Magnesium deficiency stimulates osteoclasts activation, due
to free radicals production [25], and it has been correlated to
impaired bone growth, skeletal fragility and osteoporosis in
rats and humans [26]. Potential mechanisms of lower bone
formation when magnesium is reduced are the reduced syn-
thesis of parathyroid hormone and of vitamin D [27].
Moreover, the mineral metabolism and the calcification in
bone are influenced by Mg ions [28] and abnormal minerali-
zation may occur when serum levels of magnesium is low
[27].
Recently, magnesium supplementation has been shown as
essential as calcium and vitamin D for bone health, acting as a
protective factor from osteoporosis and osteoporosis-related
fractures, [29].
Therefore, magnesium may be a good alternative as adju-
vant on implants surfaces, especially in patients with
compromized bone conditions. Thus, the objective of the cur-
rent study was to investigate the effects of magnesium during
the initial phases of implant healing and in particular, to study
the biological pathways that are involved in the bone healing




Mini-screws of titanium grade IV (Neodent, Curitiba, Brazil),
with 1.5 mm diameter and 2.5 mm length, were used for this
study. The implants had originally a turned surface, as indi-
cated by the manufacturer.
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The screws were coated with a TiO2 layer, through the
evaporation-induced-self-assembly (EISA) method, as previ-
ously described [22, 30].
In brief, a Pluronic® P123 template was used as precursor
and was diluted in absolute ethanol. A titania precursor mix-
ture containing titanium(IV)ethoxide (Aldrich) and hydro-
chloric acid (HCl, 37%, Aldrich) was added and mixed. The
mixture was deposited on the mini-screws by spin coating for
1 min at 7500 rpm. Thereafter, the surfaces were dried over-
night to allow complete self-assembly of the TiO2 structure.
The samples were then heated from room temperature to
350 °C (temp increase 1 °C/min). Once reached 350 °C, the
samples were kept at this temperature for 4 h.
This method has demonstrated to produce a mesoporous
titania layer with a 3D cubic structure, with pores of approx-
imately 6 nm in diameter [31].
The coated screws were immersed in magnesium chloride
(MgCl2) solution at 10 mg/ml concentration, serving as the
source of magnesium ions, which were deposited into the
mesoporous matrix by physical deposition. The Mg ion depo-
sition was performed on 50 screws, while the other 50 were
left as native mesoporous titania, without Mg addition, and
served as controls.
After preparation, the surfaces were characterized using
scanning electron microscopy (SEM) with a Leo Ultra55
FEG Instrument (Zeiss, Oberkochen, Germany) at an acceler-
ating voltage of 5 kV. Chemical analysis of the surface was
performed with energy dispersive spectroscopy (EDX) at a
voltage of 12 kV.
In addition, the quantity of Mg ions absorbed in the coating
was analysed by inductively coupled plasma-sector field mass
spectrometry (ICP-SFMS). Three implants loaded with Mg
ions and three control implants were used for this analysis.
The implants were immersed in 70% nitric acid (HNO3) for
24 h. The immersing media was then analysed with ICP-
SFMS.
Animal experiment
The current animal study in rats was approved by the French
ministry for research after ethical review in accordance with
the European directive 2010–63 and conducted at the Centre
De Recherce Biomédicale, Ecole National Vétérinaire
d’Alfort, Maisons Alfort, France.
Twenty-four Sprague Dawley female rats, 6 months old,
were included in this study. Osteoporosis-like conditions were
induced in the rats through ovariectomy and a low-calcium
diet. In brief, the rats were anesthetized through inhalation of
isoflurane 1% dissolved in O2. The skin of the abdomen was
shaved and then cut along the linea alba. The abdominal mus-
cles were dissected to access the peritoneal cavity. The ovaries
were located and exposed by gentle retraction. Thereafter, the
uterine tube and the ovaries were identified, and finally a
Vicryl 4.0 suture was sutured around the distal part of the
tubes. The ovaries were thereafter cut and removed.
The animals were provided with antibiotics and analgesics
after the surgery. They were kept two or three per cage and
were allowed to move freely.
Post-operatively, the rats were fed a low-calcium diet,
which contained 0.1–0.2% of calcium, in order to induce an
osteoporotic situation. This diet was continued throughout the
experimental period.
Three months after ovariectomy, the rats were anesthetized
with the same procedure. An incision was made in the skin
over the medial face of the tibia and femur. A full-thickness
periosteal flap was elevated and the medial tibia plate, as well
as the femoral distal medial epicondyle, was exposed.
Osteotomies were created with a sequence of 1-mm- and 2-
mm-diameter burs, under constant irrigation of sterile saline
solution. The mini-screws with or without magnesium doping
(test and control groups) were randomly allocated to both
sides of the hind limbs. Each rat received one screw in each
tibia and one screw in each femur, for a total of four screws per
animal, two tests and two controls.
After 1, 2, and 7 days of healing, the rats were euthanized
with a pentobarbital overdose.
After 1 and 2 days of healing, the implants and the sur-
rounding bone were explanted from the tibiae and femurs and
fixed in 70% ethanol for further histological processing.
At the 7-day sacrifice, the implants in the tibia were
explanted and fixed with 70% ethanol for further histological
examinations, while the implants in the femurs were retrieved
together with a small amount of surrounding tissue and were
placed in RNAlater® buffer (LifeTechnologies, Thermo
Fisher Scientific, Waltham, USA) and stored at −80 °C until
further processing.
Non-decalcified histology
The explants preserved in 70% ethanol were de-hydrated in
ascending ethanol concentrations for 4 weeks. Afterwards,
infiltration in methylmetacrylate resin (Technovit 7200,
VLC; Hereaeus Kulzer, Wehrheim, Germany) was performed
for 5 weeks. The samples were then embedded in the same
resin and polymerized under UV-light for 3.5 h.
The samples were then cut along the longitudinal axis of
the implants with Exakt saw (Exakt Apparatebau, Nordertedt,
Germany) and were grinded down to a thickness of approxi-
mately 40 μm.
The sections were stained with toluidine blue-pyronin g
(Histolab, Göteborg, Sweden). They were then observed at
the optical light microscope (Eclipse ME600; Nikon, Tokyo,
Japan).
To observe the effects of magnesium in the tissues sur-
rounding the implants, we selected a region of interest (ROI)
on each histological slide (Fig. 1) and the amount of new bone
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formed within that ROI was calculated as percentage (NB%)
over the total area of the ROI, excluded the implant, with the
software NiS Elements BR 4.30 (Nikon Instruments, Japan).
Gene expression analysis by means of superarrays
The first step for the gene expression analysis was the purifi-
cation of ribonucleic acid (RNA) from the cells attached to the
implant surfaces. After thawing on ice, all samples were treat-
ed with 1× PBS prior to extraction to dissolve salt crystals
formed around the implants.
ß-Mercaptoethanol RLT buffer was used to release the cells
from the surface of the implants. Total RNAwas recovered by
spin columns using the RNeasy Micro kit Cat #74004
(QIAGEN, Hilden, Germany), according to manufacturer’s
instructions. During extraction, all samples were DNase treat-
ed with RNase free DNase Set #79254 (QIAGEN, Hilden,
Germany) to reduce gDNA contamination.
The RNA from the samples was reverse transcribed in
20-μl reactions using RT2 First Strand Kit #330401
(SABiosciences, QIAGEN, Hilden, Germany) to generate
cDNA. A total of 20 μl of cDNA was generated from each
sample.
The cDNA samples were stored in −20 °C until the quan-
titative polymerase chain reaction (qPCR) was performed.
For the qPCR, RT2 Profiler PCR arrays (SABiosciences,
QIAGEN, Hilden, Germany), in the format of 96-well plates,
were used. The catalogued arrays for Rat Osteogenesis
(PARN-026Z) and Rat Osteoporosis (PARN-170Z) were se-
lected for this study. The arrays allow profiling 84 genes of
interest at the same time, related to a specific pathway, and
they include 5 suggested genes to use as reference and 7 con-
trols (Supplement material Tables 1 and 2).
The qPCR reaction mixture consisted of 1350 μl of 2× RT2
SYBR Green Mastermix (SABiosciences, Qiagen, Hilden,
Germany), 102 μl of cDNA template, previously diluted with
91 μl of nuclease-free H2O and 1248 μl of nuclease-free H2O.
A total of 25 μl of mixture was added to each well, which
contained lyophilized primer assays.
The thermocycling conditions consisted of 10 min at 95 °C
and then 40 cycles of 15 s at 95 °C and 1 min at 60 °C of a
CFX Connect 96™ thermocycler (Bio-Rad, Hercules, CA,
USA), which collected also the fluorescence intensity data
after each cycle. Dissociation curves were performed for each
well with the following melting curve program: 65 to 95 °C
with 0.5 °C step increase for 5 s each step.
The data analysis was performed using the CFX Manager
Software 3.0 (Bio-Rad, Hercules, CA, USA) with the normal-
ized relative quantification method. The normalized expres-
sion of genes in the test group was calculated relative to the
expression in the control group.
Statistical analysis
Statistical tests used to analyse the influence of the magnesium
doping on the bone healing were the non-parametric
Wilcoxon signed rank test for the histomorphometrical data
(SPSS 22.0 software) and t test for the gene expression data
(CFX Manager 3.0 Software, Bio-Rad, Hercules, CA, USA).
Statistical significance level was set at p < 0.05.
Results
Surface analysis
A representative image of the thin mesoporous TiO2 surface is
presented in Fig. 2a. It shows the high porosity level achieved
with our treatment, with homogenously distributed pores, fac-
ing out from the surface. The coating thickness was assessed
in an area with a scratch and was approximately 200 nm
(Fig. 2b). No differences were observed between the coatings
with or without magnesium ions.
The successful loading of magnesium ions in the mesopo-
rous layers was confirmed by EDX and by ICP-SFMS. The
native mesoporous surfaces were composed of oxygen
(43.10%), titanium (55.14%) and carbon (5.39%), as detected
with EDX. On the mesoporous surfaces loaded with Mg,
0.81% of Mg was detected with the EDX, and the rest was
oxygen (47.90%), titanium (45.09%) and carbon (6.18%).
The amount of carbon is within the normal level of non-
carbon-containing specimens.
Fig. 1 Light microscopy image of an implant in rat tibia. The bone
cortical thickness is small and some areas of bone degeneration are
visible. The appearance of the bone is suggestive of osteoporotic
conditions. The red square represents the region of interest selected for
the histomorphometrical measurements. The new bone formation (NB%)
was calculated as the area filled with new bone over the area within the
red rectangle, excluded the part occupied by the implant (in red)
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The amount of Mg ions in coated implants, measured with
ICP-SFMS, was on average 13.09 μg. NoMg was detected in
the control implants.
Histology
The successful induction of the osteoporotic conditions in the
ovariectomized rats was confirmed on light microscopy im-
ages of the histological sections of the tibiae and femurs. The
aspect of the bone in the femoral heads of the rats was trabec-
ular, with big medullar spaces and reduced area occupied by
bone, while in the tibia, the cortical region was thin and
showed signs of degeneration and the bone density appeared
to be considerably low (Fig. 1).
The images at day 1 of healing revealed that the implant
surfaces were surrounded with a loose network of thin fibres,
slightly stained, adherent to the implant surfaces. Cells extrav-
asated from blood vessels were found (red blood cells, plate-
lets and leucocytes) within the plot of fibres. Occasionally,
osseous fragments, remnants of the drilling process, were
found around the implants. The cells close to the implant
surfaces had a flattened aspect (Fig. 3a). Cells with fine cyto-
plasm granules suggestive of mast cells were clearly localized
in the proximity of the implants (Fig. 3b). The area of the thin
cortical region engaged with the screws showed cracks and
bone debris, as a consequence of the drilling process.
No substantial difference was noticed between the test and
control implants.
At day 2, the blood clot appeared thickened and adherent to
the implant surfaces, filling the space between the osteotomy
and the implant surfaces. The fibrin matrix was thickened on
the surfaces of the implants and in the bottom of the threads.
The aspect was suggestive of organized blood clot (Fig. 4).
On the specimens at 7 days, it was observed that the blood
clot and the granulation tissue were substituted by connective
tissue stroma with areas of clearly visible osteoid formation.
At this healing time, woven bone was already visible both on
the edges of the old bone and bone fragments and at the
implant surfaces (Fig. 5). The histomorphometrical analysis
revealed that the bone formation was about two times more
pronounced around theMg-releasing implants than around the
implants without magnesium (NB% 3.9 vs. 2.1% within the
ROI respectively, p = 0.028).
Gene expression
The effect of magnesium release on the expression of genes
involved in the pathways of osteogenesis and osteoporosis
Fig. 3 Light microscopy images of histological slides of a magnesium-
loaded (a) and a control (b) specimen 1 day after implantation. A loose
network of fibres surrounds the implant surfaces and adheres to them.
Extravasated blood cells are recognizable in the blood clot. Cells close to
the implant surfaces have a flattened shape and a fibroblast-like aspect
(yellow arrows). Cells with fine cytoplasm granules suggestive of mast
cells are visible in the proximity of the implant (red arrowheads).
Magnification ×1000. Toluidine blue staining
Fig. 2 SEM micrographs of the
titania mesoporous films on the
implant surfaces. a The thin
mesoporous film shows a high
degree of porosity. b An area in
the mesoporous film has been
scratched to visualize the
thickness of the coating
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was investigated by means of qPCR for the cells adherent to
the implant surfaces.
The stability of the expression of the five reference
genes (ACTB, B2M, HPRT1, LDHA, RPLP1) was
checked through an algorithm integrated in the CFX
Manager software, and ACTB was excluded as its ex-
pression varied too much around samples. The other
four genes were suitable (coefficient of variance below
0.5 and M value below 1) and were used for the nor-
malization of the input RNA quantity in each sample.
The internal positive controls indicated no amplifica-
tion interferences. No amplification curves were detect-
ed in the genomic DNA control (RGDC). The values of
reverse transcription controls were within the limits sug-
gested by the manufacturer, indicating that the reverse
transcription was successful. The melting curves data
revealed that the reaction was specific and no primer-
dimers were detected.
The amplification was unsuccessful for the gene IHH,
meaning that not enough copies of mRNA were originally
present in the samples.
The following osteogenesis-related genes were upregu-
lated (fold-change in expression higher than 3) for the
magnesium-releasing samples: BMP6, COL14A1,
COL2A1, CSF3, VCAM1 and VEGFA; however, only
BMP6 reached a level of statistical significance
(R = 3.8; p = 0.027).
The downregulated genes were SOX9, SMAD3 and
TGFBR3, but none of these genes’ downregulation was sig-
nificant (Fig. 6).
Fig. 5 Light microscope images of magnesium-loaded (a and c) and
native (b and d) mesoporous titania coatings of titanium implants after
7 days of healing. The blood clot is not visible anymore and it has been
substituted by a granulation tissue where vascular structures are forming
(yellow arrows). Woven bone is forming from the surfaces of the mother
bone, but also on the surfaces of the implant (red arrows). Areas of
osteoid formation are observable. Higher amount of new bone is found
around the Mg-loaded surfaces compared to the controls. Images a and b
×100 magnification. Images c and d, ×400 magnification. Toluidine blue
staining. Image e displays the box plot (e) of the histomorphometrical
results of new bone area (NB%) that filled the region of interest. The
central line of the box plot displays the median of the groups while the
degree sign displays an outlier of the samples. The difference between the
group is statistically significant (p = 0.028)
Fig. 4 Light microscope images of test (a) and control (b) specimens
after 2 days of healing in rat bone. The blood clot appears more organized
and more intensely stained than at day 1. A densely organized fibrin
network, containing a great number of cells, adheres to the implants
surfaces, especially in correspondence of the implant thread valleys.
Magnification ×400. Toluidine blue staining
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Discussion
In previous investigations, the effects of the local administra-
tion of Mg ions from mesoporous coatings on the bone an-
chorage of titanium implants were explored and positive out-
comes in healthy bone were noted [22, 23]. Magnesium-
doped titanium implants required higher reverse torque
strength in order for them to be removed compared to non-
doped controls. This biomechanical performance was corre-
lated with higher amount of bone ingrowth within the threads
of the magnesium specimens [23]. In addition, the presence of
magnesium ions stimulated an osteogenic environment in the
peri-implant sites, with upregulation of osteoblastic markers
such as osteocalcin, runt-related transcription factor 2
(RUNX2) and insulin growth factor 1 (IGF1) [23].
Based on the outcomes from the previous studies, we tested
the hypothesis that sustained release of magnesium ions from
mesoporous coatings can be beneficial for the early
osseointegration even in compromized situations such as the
osteoporosis.
Osteoporotic-like conditions were successfully induced in
female rats by means of ovariectomy (OVX) and low-calcium
diet for 90 days. Considering the reports that attest the predict-
ability of this protocol in inducing osteoporotic/osteopenic
conditions in the rats [32], it was decided to not include sham
OVX control animals nor standard diet fed animals for animal
use reduction reasons, accordingly with European standards in
animal care. As observed on the histological slides, the result
of the oestrogen deficiency and of the reduced mineral intake
was that the animal showed low bone volume, with thin cor-
tical bone in the tibia and scarce trabeculae both in the tibia
and in the femur.
After the insertion of titanium mini-screws coated with
mesoporous titania films either with (test) or without
(control) Mg ions, we observed a significant increase in
woven bone formation during the first week of healing for
the Mg-releasing implants compared to the control implants.
In addition, the pathway-focused gene expression analysis
showed a significant upregulation of BMP6 in the test speci-
mens. Other major genes described as having a role in osteo-
genesis exhibited major changes in their expression, but the
size of our experimental groups did not allow us to demon-
strate a statistical significance for these. The statistical sample
size has been chosen to characterize the effect ofMg treatment
on bone histology, based on our group former experiences
with Mg-loaded implants in healthy bones and expecting a
comparable effect. In addition, we performed power analysis
and we found that a number of 6 samples per group was a
sufficient sample size to identify statistical differences in the
expression of genes with a large effect size, with a power of
90%.
These results are in accordance with previous findings that
the incorporation of approximately 10% of magnesium in hy-
droxyapatite coatings of titanium screws was found to im-
prove the biological fixation of implants in osteoporotic bone
at 12 weeks of healing [33]. However, the molecular pathways
involved in the specific cell responses elicited by the magne-
sium release had not been previously explored in osteoporotic
conditions.
The results of the current study suggest that the effect of
magnesium could be mediated by BMP6 upregulation. BMP6
is part of the bone morphogenetic family. Similar to other
BMPs, BMP6 plays an important role in the induction of
osteogenesis. Of interest is that the BMP6 has a functional
relationship with 17β-estradiol (E2), the female gonadal ste-
roid responsible for osteoporosis in postmenopausal women.
The expression of BMP6 in foetal osteoblast cell lines is spe-
cifically stimulated by the administration of E2, while the oth-
er BMPs were less affected [34]. As mentioned above,
oestrogen deficiency favours osteoporosis through a
Fig. 6 Bar chart of the relative normalized expression of genes involved
in the osteogenesis and osteoporosis pathways. Only genes that presented
a difference in expression of threefolds or more between the test and the
control specimens are displayed. The mRNA quantity for each gene was
normalized against four reference genes (B2M, HPRT1, LDHA, RPLP1).
* = p < 0.05
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diminished control over osteoclasts formation and activity that
results in bone loss. But oestrogen deficiency elicits also a
reduction in the bone regeneration capacity [35], probably as
a consequence of the decreased expression of BMPs, and es-
pecially BMP6 [36]. This relationship between BMP6 and
oestrogens prompted researchers to test BMP6 as an anabolic
agent to promote bone matrix formation in osteoporosis.
Interestingly, the systemic administration of BMP6 in ovari-
ectomized rats could restore the bone volume and the bone
mechanical characteristics at a level comparable to those of
healthy controls [36]. Another study explored the potential of
the implantation of stem cells overexpressing BMP6 in verte-
bral defects of mini pigs and showed that the overexpression
of BMP6 induced considerable bone regeneration, while only
minor new bone filling was found in the controls [37].
However, some problems exist with regards to the local and
systemic application of BMPs due to their high costs and
potential side effects of the administration of recombinant
growth factors [35].
Thus, the finding that Mg can significantly increase the
endogenous BMP6 expression in the vicinity of the implant
suggests that Mg doping may be a relative affordable and safe
alternative to stimulate an anabolic response around implants
placed in osteoporotic sites.
Another reason that may explain the improved perfor-
mance of the implant with incorporated Mg is that the pres-
ence of Mg2+ in cell culture media has been reported to pro-
mote the direct adhesion of cell pseudopodia to substrates,
probably via an integrin-mediated mechanism [38]. Mg ions
are more effective than any other divalent cations (calcium,
strontium and barium) in inducing cell attachment and spread-
ing to different substrates [39]. This was confirmed in a study
in which polished titanium plates were hydrothermally treated
with MgCl2 solution, and gingival epithelial cells and fibro-
blastic cells were cultured on them to test for cellular adhesion
[40]. In the study, it was shown that theMg groups displayed a
much stronger attachment of fibroblastic cells, but not of ep-
ithelial cells, to the titanium substrate compared to untreated
and to CaCl2-treated titanium plates [40]. The fibroblasts
showed higher development of actin filament, more
lamellopodia and higher signal of cytoplasmic vinculin, which
is a sign of attachment [40]. Similarly in the current study, we
could observe flattened fibroblastic-like cells on the surfaces
of theMg-treated implants as soon as day 1 and it was possible
to notice a slight increase of attachment for the Mg-loaded
surfaces, although the differences were not statistically signif-
icant. Especially in those cases with reduced bone volume and
consequent risk of implant micromotion, the promotion of cell
adhesion and spreading may be beneficial for rapid
osseointegration, decreasing the risk of implant loosening.
One further benefit of Mg on bone health is the stimulation
of vascularization [27]. It has been suggested that magnesium
deficiency can cause decrease in blood vessels formation and
in their volumes and thus in blood supply, which can be an
indirect cause of osteoporosis development [27]. On the con-
trary, Mg supplementation helps endothelial cell proliferation
and function [41], which may well contribute to rapid
osseointegration. In line with that hypothesis, we observed a
faster organization of new blood vessels around the test im-
plants and also a marked upregulation of VEGFA, a growth
factor for vascular endothelial cells, despite the difference was
not significant.
Furthermore, it has been discovered that VEGF pro-
duced by osteoblasts is a potentially crucial factor for the
differentiation of MSCs toward bone forming cells rather
and to adipocytes [42]. The mechanism leading to this ef-
fect is intracrine, meaning that the VEGF released by the
osteoblasts produces an effect on osteoblasts themselves.
Knock-out mice for this factor did show osteoporotic bone
and higher amount of fat cells in the bone marrow, as
compared to a normal individual [42]. Therefore, impair-
ment in VEGF production could be another pathway that
leads to the onset of the osteoporotic conditions in patients.
In the current study, the release of Mg ions from the im-
plant surfaces stimulated the expression of this gene too
and that could be correlated to a higher amount of new
bone formation compared to controls without Mg.
We observed histologically a similar progression of
healing for the test and control groups. One day after
insertion of the implants, hematoma was the predominant
aspect in the tissues around the implants. Cells extrava-
sated from the interrupted blood vessels, especially red
blood cells, platelets and leucocytes, were found in the
areas around the implants and within the matrix of fibrin.
As well, leucocyte residents in the bone and bone marrow,
such as mast cells and polymorphonuclear leucocytes,
were found in the proximity of the implants. All these
cells and fibrin filaments are known to contribute to the
formation of the blood clot and successively to the acti-
vation and the recruitment of stromal and endothelial cells
for the healing of the defect and the formation of an in-
terface with the implant surfaces [43]. After 7 days, the
initially formed hematoma and blood clot were substituted
by bone and blood vessels forming cells and newly
formed bone was visible around the implant surfaces.
The amount of new bone formation was significantly
higher for the magnesium-releasing surfaces compared to
the native mesoporous titania substrates, suggesting that
the release of magnesium ions stimulates a faster bone
formation in the first days of healing.
We chose to investigate the cellular and molecular ef-
fects of magnesium in the initial phases of the establish-
ment of bone fixation because we hypothesized that the
influence of magnesium release would have been the
greatest shortly after implant insertion. A recent work
from Cecchinato and colleagues, in which mesoporous
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titania thin films were coated on a quartz crystal and ad-
sorption and release profile of Mg ions were studied using
quartz crystal microbalance with dissipation (QCM-D),
showed that the mobilization of Mg ions from the meso-
porous carriers is initially rapid and then it is followed by
a sustained release [44]. It was therefore speculated that
this burst release would interact with the surrounding en-
vironment immediately after implant insertion. The selec-
tion of these short time points for evaluations is a poten-
tial limitation of the present investigation, as it does not
provide information on the long-term performance of
osseointegration of the studied implants. However, the
rat is known to have a much faster bone turnover than
humans and, therefore, 7 days in rats represent a longer
healing time in humans. In addition, evidence from clin-
ical studies showed that osteoporosis does not decrease
the long-performance of implants, when osseointegration
is already established, but can constitute a risk of failure
during the early phases of implant healing, due to the
higher instability of implants placed in low density bone
and, thus, the increased possibility of micromotions [9].
Therefore, a surface modification which increases the
bone formation and the bone mineralization in the first
weeks of healing might be of interest to reduce the risk
of early implant failure, especially for those patients with
other concomitant conditions, as smoking or bruxism.
Furthermore, the positive effects of magnesium doping
on the amount and strength of osseointegration were ob-
servable even at longer healing times in a rabbit healthy
bone [22, 23].
Another potential limitation of the present study is the
substantial difference in bone metabolism, bone remodel-
ling and bone anatomy of the rat compared to humans, as
for example rat bone lacks a well-developed Haversian
canal system, which is present in human bone [32].
However, the rat is still considered the elective animal
model in orthopaedic research for the study of osteopenic
and osteoporotic bone, thanks to the extensive knowledge
that exists on the rat skeleton and the possibility to mimic
the human postmenopausal osteoporotic conditions in rats
with very good predictability [32]. For this reason, the US
Food and Drug Administration recommends that the pre-
clinical evaluation of agents for the prevention or treat-
ments of osteoporosis always includes tests in ovariecto-
mized rats.
In the current study, it was decided to employ a tibia
and femur model to test implant osseointegration. A dis-
advantage of the selection of long bone models to study
oral and maxillofacial implants is that the implants could
not be prosthetically loaded during the course of the
study. It can be hypothesized that the implants did not
undergo the same biomechanical stimulation as in the
jaws, making it difficult to generalize the results for the
clinical situations. However, it has been suggested that the
morphology of the proximal tibia resembles that of the
anterior mandible, with a thick cortical bone encapsulat-
ing bone marrow, and the distal femoral epiphysis resem-
bles the less dense trabecular bone of the posterior maxilla
[45]. These regions are also easier to access and larger
implants can be installed there than in rat jaws.
Therefore, tibia and femur models are considered an ade-
quate approximation of the intra-oral anatomical locations
and they are extensively employed to investigate the tis-
sue compatibility and bioactivity of oral implants [45]. In
addition, the current study aimed to give and insight
through gene expression analysis to the molecular pro-
cesses of bone healing that occur in the bone in proximity
of the implant surfaces in correlation with Mg release and
it can be speculated that similar pathways are activated in
distinct anatomical locations.
The potential benefits of Mg ions release in inducing the
early formation of a bone-to-implant interface in bone sites
with osteoporosis make this surface treatment an interesting
candidate for continued studies. The further development and
implementation of Mg-releasing surfaces, tailored for implan-
tation in compromized situations, may lead to improvement of
implant fixation in those patients with osteoporosis.
Conclusions
We evaluated the influence of a local release of Mg ions from
mesoporous titania films on the early phases of implant fixa-
tion in an osteoporotic animal model. The results showed that,
subsequently after implant placement, the coagulum formed
around the implants. Woven bone formation was already vis-
ible after 7 days of implant installation and the new bone
volume around the screws was significantly higher for the
specimens with magnesium.
The gene expression profiling of markers involved in the
pathways of osteogenesis and osteoporosis revealed a signif-
icant upregulation of BMP6, a marker specifically associated
with oestrogen and with a strong anabolic activity in osteopo-
rotic bone, around the magnesium-doped surfaces.
Despite some care should be applied before generaliz-
ing these results to the clinical situation, considering the
selection of a rodent model compared to human, the cur-
rent data indicate that the addition of magnesium in meso-
porous implant coatings may enhance the initial stimula-
tion of osseointegration in patients with osteoporosis.
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